Clinical trials list

ALTG Clinical trials list

Active Trials – Recruiting or in Study Start-Up

The following ALTG trials are recruiting or in the study start-up stage.

Trial  Number Title StatusMore Information
ALTG 16/009
Phase II, single arm trial to assess the efficacy and tolerability for patients with the use of Durvalumab and Tremelimumab with Chemotherapy in metastatic EGFR non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors. RecruitingTrial summary
ALTG 13/008
Efficacy of early referral to palliative care for improving quality of life and health care resources following recent diagnosis of advanced thoracic malignancies.RecruitingTrial Summary
ALTG 16/007
A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitorRecruitingANZCTR
ALTG 18/001
DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trialIn
ALTG 19/003
An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patientsIn startupSynopsis

Trials In Follow Up (closed to recruitment)

Trial Number TitleStatusMore Information
ALTG 16/005
Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancerClosed to recruitmentTrial Summary
ALTG 14/001
A phase III prospective double-blind placebo-controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancerClosed to recruitmentTrial Summary
ALTG 15/003
A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run inClosed to recruitmentANZCTR
ALTG 14/002
A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapyClosed to recruitmentTrial Summary
ALTG 16/012
Phase II trial to assess the overall survival benefit for patients with the use of Nivolumab and Ipilimumab in limited-stage small cell lung cancer (SCLC) after chemo-radiotherapy Closed to recruitmentTrial Summary
ALTG 15/004
A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With High-Risk, Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Closed to recruitmentTrial Summary

Cobadged/ Endorsed Trials

The following trials have been endorsed by the ALTG.

Trial Number Title StatusMore Information
ALTG 16/013
Activities and influence of the specialist lung cancer nurseIn development
ALTG 16/011
TROG 16.03
Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (CORE)Closed to
ALTG 13/002
Health Related Quality of Life in Malignant MesotheliomaCompletedANZCTR
ALTG 13/004
Do lung cancer patients who receive telephone or on-line support have better wellbeing outcomes than those who receive a booklet only.CompletedANZCTR
ALTG 10/001
TROG 11.03
Randomised phase 3 trial of high dose palliative radiotherapy (HDPRT) vs concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/ small volume metastatic NSCLC not suitable for radical chemo-radiotherapyClosed to follow upANZCTR
ALTG 13/003
Testing an online resource to promote sexual wellbeing for both patients and their partnersCompletedANZCTR
ALTG 15/001
TROG 13.03
A randomised phase 2 trial to test the feasibility of randomising patients with peripheral stage I NSCLC to either Stereotactic Ablative Radiotherapy (SABR) Or SurgeryIn development
ALTG 13/001
TROG 13.01
Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung: a randomised phase 2 trialClosed to recruitment
ALTG 18/002
TROG 17.02
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain MetastasesOpen to recruitmentANZCTR
Exceptional Responders Program
Malignant pleural mesothelioma sub-groupOpen to recruitmentMore information
Referral form
MoST 8
ALTG 20/001
A single arm, open label, signal seeking, phase II trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations (entry via ASPiRATION or MOST platform)In development
MoST 12
ALTG 20/002
A single arm, open label, phase II trial of vemurafenib and cobimetinib in patients with advanced tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling. (entry via ASPiRATION or MOST platform)In development
MoST 13
ALTG 20/003
A single-arm, open-label, phase II trial of entrectinib in patients with advanced tumours harbouring NTRK or ROS1 gene alterations detected by comprehensive genomic profiling (entry via ASPiRATION or MOST platform)In development
MoST 14
ALTG 20/004
A single arm, open label, phase II trial of alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling.(entry via ASPiRATION or MOST platform)In development

Completed/Closed Trials

Trial  Number Title Publications
ALTG 16/004
A phase 2 study of nivolumab with radiotherapy or nivolumab with ipilimumab in the treatment of small cell lung cancer brain metastasesTerminated. Funding withdrawn.
PA in Lung (PAL)
ALTG 08/001
Physical Activity in Lung cancer patientsAnnals of Oncology, Vol 28, Issue 8, Pages 1889-1897, August 2017
ALTG 12/003
Chemotherapy Utilisation for Malignant MesotheliomaAsia-Pacific Journal of Clinical Oncology, Vol 11, Issue 1, Pages 85–92, March 2015
ALTG 04/001Randomized comparison of first line docetaxel/gemcitabine doublet chemotherapy versus sequential single agent chemotherapyLung Cancer, Vol 49, Supplement 2, Pages S263, July 2005
ALTG 04/003
Maintenance Thalidomide in Mesothelioma PatientsThe Lancet Oncology, Vol 14, No. 6, Pages 543–551, May 2013
ALTG 04/009
Lung Cancer Patient PreferencesLung Cancer, Vol 95, Pages 8-14, May 2016
ALTG 06/003
A randomised, phase III trial of adding nitroglycernin to first line chemotherapy in advanced non-small cell lung cancer.Annals of Oncology, Vol 26, Pages 2280-2286, September 2015
ALTG 09/001
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancerEuropean Journal of Cancer, Vol 50, Issue 4, Pages 706 - 712, March 2014
ALTG 09/002
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancerThe Lancet Oncology, Vol 15, No. 12, Pages 1379-1388, Nov 2014
ALTG 09/004
A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural MesotheliomaLung Cancer, Vol 81, Pages 422-427, May 2013
ALTG 10/002A Pilot Study To Develop A Classification Algorithm For Identifying Patients With Adenocarcinoma Of Lung Suitable For Individualized TherapiesStudy completed late 2011
ALTG 10/003Implementing standardised PET procedures for scanning, data collection and reporting in patients with NSCLC across Australia’s ALTG sites: A feasibility study.Study completed late 2011
ALTG 10/004Limiting the functional decline of patients with advanced non-small cell lung cancer.Journal of Thoracic Oncology Vol 7, Issue 9, July 2011
Surveillance in patients with MPM
ALTG 17/001
A prospective single arm phase II trialTerminated. Funding withdrawn.
ALTG 09/005
TROG 09.02
A Randomised Phase III Trial of Highly Conformal Hypofractionated Image Guided ("Stereotactic") Radiotherapy (HypoRT) Versus Conventionally Fractionated Radiotherapy (ConRT) for Inoperable Early Stage I Non-small Cell Lung Cancer (CHISEL)The Lancet Oncology Vol 20 No 4, pp 494-503, April 2019.